Novartis's Tislelizumab Takes First Step On US Approval Path
Aiming To Reach Crowded Checkpoint Inhibitor Market
Executive Summary
Novartis has filed the PD-1 inhibitor tislelizumab, licensed from BeiGene, for second-line esophageal cancer with the FDA, the first submission outside China for the closely-watched therapy.
You may also be interested in...
Novartis/BeiGene Likely To Struggle In Crowded PD-1 Space Despite Positive First-Line Data
Merck’s Keytruda and BMS’s Opdivo could be tough competitors in esophageal cancer, but the Novartis/BeiGene partnership also has an anti-TIGIT drug up its sleeve.
Novartis’s John Tsai On The Four Philosophies Driving R&D
Scrip spoke with global development head and chief medical officer John Tsai about the factors Novartis considers when it decides which R&D programs to advance, including externally sourced assets.
Novartis Hopes For Canakinumab In Lung Cancer Nosedive
After deciding to examine canakinumab's potential in lung cancer on the back of the CANTOS cardiovascular trial, Novartis designed a major late-stage program in oncology for the interleukin-1 beta inhibitor. The second of those CANOPY trials has just come crashing down.